| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IP | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| IF | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 |
<!--
Western Blot
-->
BCL-10 (B-cell lymphoma 10) is a key adaptor protein involved in innate and adaptive immune signaling pathways. Initially identified through its association with chromosomal translocations in mucosa-associated lymphoid tissue (MALT) lymphomas, BCL-10 plays a critical role in regulating NF-κB activation, a central mediator of inflammatory and immune responses. Structurally, BCL-10 contains a caspase recruitment domain (CARD) that facilitates protein-protein interactions, enabling its participation in signaling complexes such as the CBM complex (CARD11-BCL-10-MALT1). This complex links antigen receptor signaling in lymphocytes to downstream NF-κB activation, influencing cell survival, proliferation, and cytokine production.
Dysregulation of BCL-10 has been implicated in various pathologies. In MALT lymphomas, chromosomal translocations (e.g., t(1;14)) lead to BCL-10 overexpression, promoting uncontrolled NF-κB activity and lymphomagenesis. BCL-10 also contributes to autoimmune diseases and chronic inflammatory conditions due to its role in amplifying immune responses. Conversely, BCL-10 can act as a tumor suppressor in certain contexts, highlighting its context-dependent functionality.
BCL-10 antibodies are essential tools for studying its expression, localization, and interactions in both physiological and pathological states. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to assess BCL-10 levels in cancer tissues or immune cells. Research utilizing these antibodies has advanced understanding of BCL-10’s dual roles in immunity and disease, offering potential therapeutic targets for modulating NF-κB pathways in malignancies and inflammatory disorders.
<!--
Immunofluorescence
-->
<!--
Flow cytometric
-->
Flow cytometric analysis of Hela cells using BCL10 mouse mAb (green) and negative control (purple).
<!--
Immunohistochemistry
-->
| Aliases | CLAP; Me10; CIPER; c-E10; CARMEN |
| Entrez GeneID | 8915 |
| Swissprot | O95999 |
| clone | 4F8 |
| WB Predicted band size | 26kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of human BCL-10 expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
以下是关于BCL-10抗体的3篇代表性文献(模拟示例，非真实文献)：
1. **"BCL-10 expression in MALT lymphoma: a diagnostic marker and role in NF-κB activation"**
- **作者**: Uno et al.
- **摘要**: 研究BCL-10蛋白在黏膜相关淋巴组织(MALT)淋巴瘤中的异常表达，揭示其作为诊断标志物的潜力，并证明其通过激活NF-κB信号通路促进肿瘤发生。
2. **"Structural characterization of BCL-10 and its caspase recruitment domain (CARD)"**
- **作者**: Zhang et al.
- **摘要**: 解析BCL-10蛋白的CARD结构域三维结构，阐明其通过寡聚化与CARD9/CARD11相互作用，调控下游炎症及凋亡信号通路的分子机制。
3. **"BCL-10 antibody application in immunohistochemical diagnosis of lymphoid malignancies"**
- **作者**: Chen et al.
- **摘要**: 评估BCL-10抗体在免疫组织化学中的应用，证实其在区分MALT淋巴瘤与其他B细胞淋巴瘤亚型中的高特异性及临床实用性。
(注：以上文献为示例，实际引用请通过PubMed或学术数据库检索真实研究。)
BCL-10 (B-cell lymphoma 10) is a key adaptor protein involved in innate and adaptive immune signaling pathways. Initially identified through its association with chromosomal translocations in mucosa-associated lymphoid tissue (MALT) lymphomas, BCL-10 plays a critical role in regulating NF-κB activation, a central mediator of inflammatory and immune responses. Structurally, BCL-10 contains a caspase recruitment domain (CARD) that facilitates protein-protein interactions, enabling its participation in signaling complexes such as the CBM complex (CARD11-BCL-10-MALT1). This complex links antigen receptor signaling in lymphocytes to downstream NF-κB activation, influencing cell survival, proliferation, and cytokine production.
Dysregulation of BCL-10 has been implicated in various pathologies. In MALT lymphomas, chromosomal translocations (e.g., t(1;14)) lead to BCL-10 overexpression, promoting uncontrolled NF-κB activity and lymphomagenesis. BCL-10 also contributes to autoimmune diseases and chronic inflammatory conditions due to its role in amplifying immune responses. Conversely, BCL-10 can act as a tumor suppressor in certain contexts, highlighting its context-dependent functionality.
BCL-10 antibodies are essential tools for studying its expression, localization, and interactions in both physiological and pathological states. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to assess BCL-10 levels in cancer tissues or immune cells. Research utilizing these antibodies has advanced understanding of BCL-10’s dual roles in immunity and disease, offering potential therapeutic targets for modulating NF-κB pathways in malignancies and inflammatory disorders.
×
